Genildo Lins

Presidente, eu vou só complementar aqui o que o doutor Felipe falou, é... Se o Ministério der seguimento ao grupo de trabalho, como ele nos informou... ele com certeza vai chegar à mesma conclusão que nós estamos expondo aqui. E por fim, presidente, agradecer pela iniciativa, isso aqui é muito importante para o setor de saúde, esse momento de fala. esse ambiente em que todos os setores que estão aqui envolvidos podem dar suas posições. para alertar sobre uma medida que pode ser tão prejudicial ao setor de saúde brasileiro. Obrigado, presidente.

it I brought the presentation They're forced me to get up. Yeah. Thank you. Thank you. Good morning to all. We, here in this audience, we are going to a big risk to repeat ourselves, because we are all in the same boat. I will try I want to highlight the points that my colleagues who had already mentioned not have been mentioned. But can you repeat the important thing? First, I like to talk about the CNSaud, I'll ask you two minutes to talk about it. We are a confederation that represents hospitals, medical and laboratories. And 85 entities sindicates vinculadas almost 870 million companies. are affiliated with the health care community, We generated 3,2 million jobs direct jobs. And we are the third largest employer in Brazil. This is the importance of health. We're talking about a good thing. of an essential service and that is the third employer of Brazil. This, growing from 2021 to 2024, which are the last data that we have been divulged by the Ministry of Work, we had a growth of 15% of jobs. and we are the sector that more empowers women. We have today, also in 2024, 84% of our work is women. So, another point of importance and importance of the health sector. . Here is a diagram of how it works, of our sindicats and federations. our relationship within the government, for the government, but I will go directly to the objective of this audience. 25% of the Brazilian people today access to health supplementary. more than 50 million people. And this number is constant in the last four years. the year that goes a little, that diminue, but the average is constant in 25%. We have some factors that make our health Boa. but also car. First, we have a medical inflection relevant. 2024 was 14%, 14,5%. There was a prevision in 2025 for 12%. but also we have one of the most modern modern health in the world. Here we offer the best treatments, we have doctors of the best and we also import technology outside. This we make it a lot of advanced. We have a characteristic here, and we have a relevant role in the private market. The technological incorporation process has been facilitated in the last few years, so this also counts in our favor. but all this is the cost. And cost, there are three ways to treat. or you make a gain of efficiency, within the next organization. You increase the lucratability of the employee, which also diminutes the interest in the service. or "repassa" to "preço". Of course, you can't increase the cost of the cost. to solve it all only with one of these points. Normally you use parts of each three, these three mechanisms of adequacy of cost. But one of them is the price. One of them can impact those 25% of the Brazilian people who access to the health supplementary in Brazil. And we have today many factors of increase of cost, and many factors of increase of cost in the private sector. We have issues of work, a scale 5x2, which, in addition to an increase of cost, has a lack of work. We live today practically in pleno emprego, in fact, statistically in pleno emprego. So we don't have in theory, a quantity available of professionals that can support this time of hours necessary. We have a PEC that was approved last week in Senado, which reduces the charge of the enfermage of the patients. We estimate that this, this PEC, has a cost of 8 billion dollars per year, a cost of 8 billion dollars, 22,5 is only for the public sector. It's a PEC that will bring money to 2,5 billion to the public sector. The technology, as I said to you, and the cost of acquiring insumos, which is the point of this audience, which is the import of import. Ah, for... was published in Resolution 852, that increased the import tax tax more than 220 products in Brazil, - Thank you. as the colleague said, first, the virus was directed to a TI, but at the end, we were we. We estimate that for hospitals, this increase of import cost, it causes a increase of cost. of 7,6% to hospitals, and of 9% to 11% for laboratories. Why 9% to 11%? Nine is acquiescence direct, and the leasing is. So, the laborator that, in order to acquire products, does leasing, has a greater impact. This is a cost. of the which leads to the increase of the cost of the health plan, which leads, in part, to increase the price for the consumer. Okay? We went to the Ministry of Development and Industry, we had a meeting with the president and the president. He formed a group of work. In this work we already had a meeting with some colleagues who will talk about and already said, they were in the group. The work group was divided into three stages. None of them were still there. Concluid. The first step Remember a resolution, the resolution, the 852, it increases, who had to 7,2% was to 7,2%; who had to 7,2% to 15% was to 15% and then 20% Thank you. We decided to focus on what was zero or less than 7,2% because of a presumption that How much of the world could have national production for these products? So we focused on these products from 37 to 40. We encaminhamos a list for the ministry and we didn't have a response. The second step is It's a work of the próprio ministério. that he would be revisited his data in a process of public consultation, or in society, to see if, in fact, The products that they say that they don't have national production, they don't have national production. So this is also with them, but it also wasn't done. And there is a third step, which is Feito The problem was solved by the 7,2% of the revision. You can achieve a ex-tarifário definitive, and then it's the work of each company that import the product. In the end of March we had the last advance, which was a concessions of Ex-Sarifario for more or less 195 products but it doesn't solve the problem. So today we have a precarious instrument Thank you. to resolve three resolutions that will stop to be divided between maio and julio. So, at least from maio, we will have a greater tributation if the Minister doesn't evaluate and conclude that that product have national production or not. And, just to finish, The process is understood the importance of the national production important for the development of our industry. We understand We also pondering that national production has to or the permission of importation, we have to observe a possible reduction of cost, which has a benefit to the population in general, Okay? and that any measure in this sense has to follow a process. And the problem of this resolution was the process, one of the problems. There was no public audience. as entities were not heard about these products And there is no instrument that, by decree, is obligatory, called analysis of regulatory impact. Not was made this evaluation. This caused a problem for the health sector, which is who we represent here, and that can, at the medium-term, be able to create a problem for society as a whole. President, thank you. No, I'll conclude. Thank you.